petct-with-68ga-nota-fap-2286-for-imaging-tendon-injuries-rat

PET/CT With [<sup>68</sup>Ga]-NOTA-FAP-2286 for Imaging of Tendon Injuries in Rat Achilles Tendon Injury Models

Tendon injuries, particularly those affecting the Achilles tendon, are common sports-related conditions that significantly impact patients&#39; quality of ...

application-of-32p-radioactive-patch-in-keloid-treatment

Application of <sup>32</sup>P Radioactive Patch in Keloid Treatment

Keloid, as a benign fibroblastic disease of the skin, is the result of excessive proliferation of fibroblasts and abnormal deposition of collagen during ...

periodic-quality-control-methods-for-spect-ct

Periodic Quality Control Methods for SPECT-CT

In the field of medical imaging, gamma cameras, single photon emission computed tomography (SPECT), and SPECT/CT are critical diagnostic tools. Quality ...

combined-application-technetium-99m-sulfur-colloid-blue-dye-for

Combined Application of Technetium-99m Sulfur Colloid and Blue Dye for Sentinel Lymph Node Detection in Early-stage Breast Cancer

Sentinel lymph node biopsy (SLNB) is the standard procedure for axillary lymph node staging in breast cancer patients, and its application has prevented ...

Zhejiang University School of Medicine

Radionuclides internal radiotherapy (RIT) is a clinically powerful method for cancer treatment, but still poses unsatisfactory therapeutic outcomes due to the hypoxic characteristic of tumor microenvironment (TME). Catalase (CAT) or CAT-like nanomaterials can be used to enzymatically decompose TME endogenous HO to boost TME oxygenation and thus alleviate the hypoxic level within tumors, but their effectiveness is still hindered by the short-lasting of hypoxia relief owing to their poor stability or degradability, thereby failing to match the long therapeutic duration of RIT. Herein, we proposed an innovative strategy of using facet-dependent CAT-like Pd-based two-dimensional (2D) nanoplatforms to continuously enhance RIT. Specifically, rationally designed 2D Pd@Au nanosheets (NSs) enable consistent enzymatic conversion of endogenous HO into O to overcome hypoxia-induced RIT resistance. Furthermore, partially coated Au layer afford NIR-II responsiveness and moderate photothermal treatment that augmenting their enzymatic functionality. This approach with dual-effect paves the way for reshaping TME and consequently facilitating the brachytherapy ablation of cancer. Our work offers a significant advancement in the integration of catalytic nanomedicine and nuclear medicine, with the overarching goal of amplifying the clinical benefits of RIT-treated patients.

A continuously efficient O-supplying strategy for long-term modulation of hypoxic tumor microenvironment to enhance long-acting radionuclides internal therapy.

Castleman disease (CD) is a rare lymphoproliferative disorder. This study is to evaluate the correlation between F-flurodeoxyglucose (F-FDG) positron emission tomography-computed tomography (PET/CT) and clinical features in CD patients, and exploring its value in distinguishing disease severity and assisting in risk stratification.

F-FDG PET/CT metabolic parameters are correlated with clinical features and valuable in clinical stratification management in patients of castleman disease.

Fatty acid metabolism plays a critical role in cancer development. In this study, a novel medium-chain fatty acid (MCFA) PET tracer, 2-[F]fluorohexanoic acid (F-FHA), was successfully synthesized with high radiochemical yield (65 ± 5.4%) and purity (>99%). Tumor radiotracer uptake at 60 min in A431, Hek293, Kpc, 4T1, Hep3b, and Lm3 xenograft models was 7.1 ± 0.4, 8.8 ± 0.6, 7.7 ± 0.5, 7.2 ± 0.4, 5.1 ± 0.3, and 4.9 ± 0.3 percentage injected dose per gram (% ID/g), respectively. Pretreatment with salicylic acid (SA), an inhibitor of medium-chain acyl-CoA synthetase (ACSM), significantly enhanced tumor uptake ( < 0.05) but showed no effect on blood uptake ( = 0.115). The biodistribution analysis demonstrated that F-FHA exhibited rapid hepatic and cardiac accumulation followed by gradual clearance, whereas tumor uptake exhibited gradual elevation within the initial 20 min and remained relatively stable through the 90 min observation period. F-FHA warranted further investigation as a potential PET imaging agent for tumors.

ArticleTotal : 4	Year
Publication title	2025
Publication title	2025
Publication title	2025
Publication title	2025

Article	Year
A continuously efficient O-supplying strategy for long-term modulation of hypoxic tumor microenvironment to enhance long-acting radionuclides internal therapy. Journal of nanobiotechnology\| PubMed ID: 38166931	2024
F-FDG PET/CT metabolic parameters are correlated with clinical features and valuable in clinical stratification management in patients of castleman disease. Cancer imaging : the official publication of the International Cancer Imaging Society\| PubMed ID: 39940060	2025
Radiolabeling and Preclinical Evaluation of 2-[F]Fluorohexanoic Acid: A Novel Medium-Chain Fatty Acid Metabolism Tracer for PET Imaging of Tumors. Journal of medicinal chemistry\| PubMed ID: 40531657	2025

Qianhe Xu

Biography

JoVE Journal Publications

Other Publications